CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Top Cited Papers
- 28 March 2025
- journal article
- review article
- Published by Elsevier in The Lancet Rheumatology
- Vol. 7 (6) , e434-e447
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseasesMedical Oncology, 2024
- CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectivesCell Biochemistry and Function, 2024
- Effects of B Cell Depletion by CD19‐Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic SclerosisArthritis & Rheumatology, 2023
- CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeJAMA, 2023
- CAR T-cell behavior and function revealed by real-time imagingSeminars in Immunopathology, 2023
- Plasmablast‐like Phenotype Among Antigen‐Experienced CXCR5–CD19low B Cells in Systemic Lupus ErythematosusArthritis & Rheumatology, 2022
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Annals of Oncology, 2022
- Current Concepts on the Pathogenesis of Systemic SclerosisClinical Reviews in Allergy & Immunology, 2021
- Updated assessment of the prevalence, spectrum and case definition of autoimmune diseaseAutoimmunity Reviews, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012